NCT04037345View on ClinicalTrials.gov

Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

November 12, 2020

Study Completion Date

November 12, 2020

Conditions
Knee Osteoarthritis
Interventions
BIOLOGICAL

SMUP-IA-01(low-dose)

A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

BIOLOGICAL

SMUP-IA-01(mid-dose)

A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

BIOLOGICAL

SMUP-IA-01(high-dose)

A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Medipost Co Ltd.

INDUSTRY

NCT04037345 - Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis | Biotech Hunter | Biotech Hunter